JP2024521878A5 - - Google Patents

Info

Publication number
JP2024521878A5
JP2024521878A5 JP2023574119A JP2023574119A JP2024521878A5 JP 2024521878 A5 JP2024521878 A5 JP 2024521878A5 JP 2023574119 A JP2023574119 A JP 2023574119A JP 2023574119 A JP2023574119 A JP 2023574119A JP 2024521878 A5 JP2024521878 A5 JP 2024521878A5
Authority
JP
Japan
Prior art keywords
halo
alkyl
pharmaceutically acceptable
acceptable salt
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032042 external-priority patent/WO2022256586A2/en
Publication of JP2024521878A publication Critical patent/JP2024521878A/ja
Publication of JP2024521878A5 publication Critical patent/JP2024521878A5/ja
Pending legal-status Critical Current

Links

JP2023574119A 2021-06-03 2022-06-03 置換インドール化合物及びその使用方法 Pending JP2024521878A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163196339P 2021-06-03 2021-06-03
US63/196,339 2021-06-03
US202163290019P 2021-12-15 2021-12-15
US63/290,019 2021-12-15
US202263346120P 2022-05-26 2022-05-26
US63/346,120 2022-05-26
PCT/US2022/032042 WO2022256586A2 (en) 2021-06-03 2022-06-03 Substituted indole compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024521878A JP2024521878A (ja) 2024-06-04
JP2024521878A5 true JP2024521878A5 (https=) 2025-06-02

Family

ID=84323595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574119A Pending JP2024521878A (ja) 2021-06-03 2022-06-03 置換インドール化合物及びその使用方法

Country Status (19)

Country Link
US (1) US20240287034A1 (https=)
EP (1) EP4346812A4 (https=)
JP (1) JP2024521878A (https=)
KR (1) KR20240017004A (https=)
CN (1) CN120081822A (https=)
AU (1) AU2022283903A1 (https=)
BR (1) BR112023025235A2 (https=)
CA (1) CA3222144A1 (https=)
CL (1) CL2023003591A1 (https=)
CO (1) CO2023016557A2 (https=)
CR (1) CR20230564A (https=)
DO (1) DOP2023000263A (https=)
EC (1) ECSP23090260A (https=)
IL (1) IL308835A (https=)
JO (1) JOP20230315A1 (https=)
MX (1) MX2023014274A (https=)
PE (1) PE20250114A1 (https=)
PH (1) PH12023553130A1 (https=)
WO (1) WO2022256586A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
AU2021414253B2 (en) * 2020-12-30 2024-05-16 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Series of piperidine-substituted benzoic acid compounds, and use thereof
EP4362933A4 (en) * 2021-06-30 2025-06-04 Apellis Pharmaceuticals, Inc. COMPLEMENT INHIBITION
EP4389742A4 (en) * 2021-08-18 2026-01-14 Xizang Haisco Pharmaceutical Co Ltd HETEROAROMATIC CYCLE DERIVATIVE CONTAINING BENZO NITROGEN AND ITS USE IN MEDICINE
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途
CA3247772A1 (en) * 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses
CN119301114A (zh) * 2022-06-07 2025-01-10 正大天晴药业集团股份有限公司 双环取代的芳香羧酸类氘代化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
CA3266935A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses
IL320661A (en) * 2022-11-14 2025-07-01 Novartis Pharma Ag Solid forms of complement factor B inhibitors
TWI869080B (zh) * 2022-11-29 2025-01-01 大陸商上海濟煜醫藥科技有限公司 苯並螺環吲哚化合物的製備及用途
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
WO2024149261A1 (zh) * 2023-01-09 2024-07-18 南京正大天晴制药有限公司 补体因子b抑制剂
EP4667465A1 (en) * 2023-02-16 2025-12-24 Haisco Pharmaceutical Group Co., Ltd. Salt of benzo-nitrogen heteroaromatic ring derivative, crystalline form, and pharmaceutical use thereof
EP4670719A1 (en) * 2023-02-22 2025-12-31 Haisco Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION OF A HETEROAROMATIC BENZO-NITROGEN RING DERIVATIVE AND ITS USE IN MEDICINE
TW202506657A (zh) * 2023-04-27 2025-02-16 大陸商上海翰森生物醫藥科技有限公司 一種哌啶基吲哚化合物的鹽及其製備方法
IL325760A (en) 2023-07-04 2026-03-01 Sitala Bio Ltd History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors
CN121889385A (zh) 2023-07-04 2026-04-17 希塔拉生物有限公司 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
CN119371402A (zh) * 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
WO2025119266A1 (zh) * 2023-12-05 2025-06-12 西藏海思科制药有限公司 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
WO2025256647A1 (zh) * 2024-06-14 2025-12-18 润尔眼科药物(广州)有限公司 化合物及其医药用途
WO2026008073A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂的剂量组合物
WO2026069246A1 (en) * 2024-09-30 2026-04-02 Novartis Ag Complement factor b inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027113B1 (ru) * 2012-05-04 2017-06-30 Новартис Аг Регуляторы пути комплемента и их применение
EP2867225B1 (en) * 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
SG11201811491YA (en) * 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途

Similar Documents

Publication Publication Date Title
JP2024521878A5 (https=)
JP2024541929A5 (https=)
JP2025504859A5 (https=)
JP2016535042A5 (https=)
JP2015515976A5 (https=)
JP2021507900A5 (https=)
JP2016514719A5 (https=)
JP2016526576A5 (https=)
JP2020537657A5 (https=)
JP2017505808A5 (https=)
JP2013509431A5 (https=)
JP2019518766A5 (https=)
JP2016514718A5 (https=)
JP2013533883A5 (https=)
JP2017538721A5 (https=)
JP2017512786A5 (https=)
JP2020502047A5 (https=)
JP2010513283A (ja) 新規なオキサジアゾール化合物
RU2009135080A (ru) Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor
JP2024521895A5 (https=)
JP2007515489A5 (https=)
JP2017532294A5 (https=)
JP2023519824A5 (https=)
JP2021510692A5 (https=)
JP2025503448A5 (https=)